A series of substituted heteroaromatic compounds containing two fused six-membered rings, tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

The present invention provides a cured product obtained by curing a curable composition including a compound represented by General Formula 1, in which a birefringence Δn (587 nm) is 0.00≤Δn (587 nm)≤0.01.
Pol.sub.1-Sp.sub.1-L.sub.1-Ar-L.sub.2-Sp.sub.2-Pol.sub.2  (General Formula 1) In the formula, Ar represents a divalent group containing a ring structure selected from the group consisting of a quinoxaline ring and a quinazoline ring; L.sub.1 and L.sub.2 each represent a single bond, —O—, —OC(═O)—, —OC(═O)O—, —OC(═O)NH—, and the like; Sp.sub.1 and Sp.sub.2 each represent a single bond or a divalent linking group; Pol.sub.1 and Pol.sub.2 each represent a hydrogen atom or a polymerizable group; and the compound represented by General Formula 1 has at least one polymerizable group. The cured product of the present invention has a small Abbe number (νd) and a large partial dispersion ratio (θg, F), and is therefore useful for production of optical members.

The present invention provides a cured product obtained by curing a curable composition including a compound represented by General Formula 1, in which a birefringence Δn (587 nm) is 0.00≤Δn (587 nm)≤0.01.
Pol.sub.1-Sp.sub.1-L.sub.1-Ar-L.sub.2-Sp.sub.2-Pol.sub.2  (General Formula 1) In the formula, Ar represents a divalent group containing a ring structure selected from the group consisting of a quinoxaline ring and a quinazoline ring; L.sub.1 and L.sub.2 each represent a single bond, —O—, —OC(═O)—, —OC(═O)O—, —OC(═O)NH—, and the like; Sp.sub.1 and Sp.sub.2 each represent a single bond or a divalent linking group; Pol.sub.1 and Pol.sub.2 each represent a hydrogen atom or a polymerizable group; and the compound represented by General Formula 1 has at least one polymerizable group. The cured product of the present invention has a small Abbe number (νd) and a large partial dispersion ratio (θg, F), and is therefore useful for production of optical members.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

The present invention describes fluorene derivatives substituted by electron-transporting groups, especially for use as triplet matrix materials in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.

The present invention describes fluorene derivatives substituted by electron-transporting groups, especially for use as triplet matrix materials in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.

An organic light-emitting device includes a heterocyclic compound represented by Formula 1, in which at least one of X.sub.1 to X.sub.4 is a nitrogen atom, and at least one is carbon atom substituted by Formula 1A:

##STR00001##

The heterocyclic compound represented by Formula 1 may have excellent electron transport capability, and the organic light-emitting device may accordingly have low driving voltage, high efficiency, high luminance, and/or long lifespan characteristics.

An organic light-emitting device includes a heterocyclic compound represented by Formula 1, in which at least one of X.sub.1 to X.sub.4 is a nitrogen atom, and at least one is carbon atom substituted by Formula 1A:

##STR00001##

The heterocyclic compound represented by Formula 1 may have excellent electron transport capability, and the organic light-emitting device may accordingly have low driving voltage, high efficiency, high luminance, and/or long lifespan characteristics.

Disclosed herein are certain 4-arylquinazoline derivatives of Formula (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

##STR00001##